A SINGLE ORAL ASCENDING DOSE STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO6836191 IN HEALTHY MALE VOLUNTEERS INCLUDING A SINGLE INTRAVENOUS DOSE OF RO6836191

Published: 16-10-2013
Last updated: 23-04-2024

The study will be performed in 2 parts, Parts 1 and Part 2. The purpose of this study is to investigate to what extent RO6836191 is tolerated. It will also be investigated how quickly and to what extent RO6836191 is absorbed and eliminated from the...

Ethical review	Approved WMO
Status	Recruitment stopped
Health condition type	Heart failures
Study type	Interventional

Summary

ID

NL-OMON40173

Source
ToetsingOnline

Brief title
RO6836191 SAD + FE study

Condition

- Heart failures
- Vascular hypertensive disorders

Synonym

cardiovascular diseases, high blood pressure

Research involving
Human

Sponsors and support

Primary sponsor: Hoffmann-La Roche
Source(s) of monetary or material Support: farmaceutische industrie

Intervention

Keyword: Cardiovascular diseases

Outcome measures

Primary outcome

safety and tolerability

pharmacokinetics of oral dosing

pharmacodynamics

Secondary outcome

pharmacokinetics after IV dosing

Study description

Background summary

RO6836191 is a new investigational compound that may eventually be used for the treatment of cardiovascular diseases. RO6836191 inhibits the production of aldosterone, a hormone which plays an important role determining cardiovascular and renal damage during cardiovascular diseases, leading to a reduction in blood pressure. This is the first time that this compound is being given to humans.

Study objective

The study will be performed in 2 parts, Parts 1 and Part 2.
The purpose of this study is to investigate to what extent RO6836191 is tolerated. It will also be investigated how quickly and to what extent RO6836191 is absorbed and eliminated from the body (this is called

pharmacokinetics). In addition the effect of RO6836191 on aldosterone levels will be investigated (this is called pharmacodynamics).

In Part 2 the effect of a low salt diet on the pharmacodynamics of RO6836191 will also be investigated. In addition, the pharmacokinetics of intravenous RO6836191 administration will be compared with oral (via the mouth) RO6836191 administration.

Study design

Part 1:
The study consists of 1 period, during which RO6836191 or placebo will be given.

In Group 1 only, first 2 male volunteers will be dosed on the same day (1 will receive RO6836191, and 1 will receive placebo) before the rest of the group will be dosed. After dosing, the safety and tolerability of RO6836191 in these volunteers will be closely monitored. If there are no concerns about the safety and tolerability, then the remaining 6 volunteers (5 will receive RO6836191 and 1 will receive placebo) will be dosed at least 1 day after the first 2 volunteers have been dosed.

A Cortrosyn test will be performed in Group 3 to 7. During this test a hormone is injected, which stimulates the production of aldosterone and cortisol. The levels of aldosterone and cortisol in blood will be determined both before and 30 minutes after injection of the hormone, by taking a blood sample. This test will be performed both before and after RO6836191 or placebo has been given.

Part 2:
The actual study will consist of 3 Periods. The time interval between the different Periods is at least 7 days. In the first 2 Periods, the study medication will be given once during a low salt and once during a normal diet. During Period 3, a single dose of RO6836191 will be given intravenously

Intervention

Part 1:
During the study the study medication will be given after a fasting period (no food or drinks) of at least 8 hours as a drinking solution at a volume of 50 to 100 milliliters. The bottle containing the study medication will be rinsed at least twice with 50 milliliters of tap water which needs to be drunk by the volunteers. Per group 6 participants will receive RO6836191 and 2 participants will receive placebo.

Part 2:

During Periods 1 and 2, the study the study medication will be given after a fasting period (no food or drinks) of at least 8 hours as a drinking solution at a volume of 50 to 100 milliliters. The bottle containing the study medication will be rinsed at least twice with 50 milliliters of tap water which needs to be drunk by the volunteers. Per group 6 participants will receive RO6836191 and 2 participants will receive placebo.
During Period 3 a 30 minute during intravenous infusion of RO6836191 will be given after a fasting period (no food or drinks) of at least 8 hours.

Study burden and risks

canula insertion in each period
single blood draws
IV dosing in Part 2, once
in Part 2, low salt diet during 1 period
2x ocular assessment with ophthalmologist in Part 1

Contacts

Public
Hoffmann-La Roche

Falcon Way, Shire Park, 6
Welwyn Garden City AL7 1TW
GB
Scientific
Hoffmann-La Roche

Falcon Way, Shire Park, 6
Welwyn Garden City AL7 1TW
GB

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age
Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

18 to 45 years of age, inclusive
BMI between 18 to 30 kg/m2 inclusive
healthy male volunteers

Exclusion criteria

suffering from hepatitis B, hepatitis C or HIV/AIDS
donation of blood over 450 mL within three months prior to screening
Participation in another investigational drug or device study within 3 months prior to dosing

Study design

Design

Study type:	Interventional
Intervention model:	Parallel
Allocation:	Randomized controlled trial
Masking:	Double blinded (masking used)
Control:	Placebo
Primary purpose:	Treatment

Recruitment

NL

Recruitment status:	Recruitment stopped
Start date (anticipated):	18-10-2013
Enrollment:	96
Type:	Actual

Ethics review

Approved WMO Date:	16-10-2013
Application type:	First submission
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	18-10-2013
Application type:	First submission
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	10-02-2014
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	26-02-2014
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
EudraCT	EUCTR2012-003502-27-NL
CCMO	NL46522.056.13